NCT03512340

Study of SRF231 in Patients With Advanced Solid and Hematologic Cancers

Completed Phase 1 Last updated 20 October 2020

What this trial tests

Phase 1 trial testing SRF231 in Advanced Solid Cancers in 148 participants. Completed in 29 September 2020.

Timeline

13 March 2018

Primary endpoint
15 September 2020

29 September 2020

Quick facts

Lead sponsor	Surface Oncology
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	148
Start date	13 March 2018
Primary completion	15 September 2020
Estimated completion	29 September 2020
Sites	3 locations across Canada, United States

Drugs / interventions tested

• SRF231 — full drug profile →

Conditions studied

• Advanced Solid Cancers — all drugs for Advanced Solid Cancers →
• Hematologic Cancers — all drugs for Hematologic Cancers →

Sponsor

Surface Oncology — full company profile →

Who can join

Adults 18 to 99, any sex, with Advanced Solid Cancers or Hematologic Cancers. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This Phase 1/1b, open-label, first-in-human, monotherapy study will be conducted in 2 parts. Part A will consist of the SRF231 monotherapy dose-escalation portion of the study, and will enroll up to 48 patients with advanced solid tumors and hematological cancers. Part B will include monotherapy expansion cohorts in advanced solid and hematologic cancers to further examine SRF231 as monotherapy (100 patients total).

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

1. Targeting cancer stem cell pathways for cancer therapy.
   Yang L, Shi P, Zhao G, Xu J, et al · · 2020 · cited 1354× · PMID 32296030 · DOI 10.1038/s41392-020-0110-5
2. Phagocytosis checkpoints as new targets for cancer immunotherapy.
   Feng M, Jiang W, Kim BYS, Zhang CC, et al · · 2019 · cited 729× · PMID 31462760 · DOI 10.1038/s41568-019-0183-z
3. Targeting macrophages in cancer immunotherapy.
   Duan Z, Luo Y. · · 2021 · cited 462× · PMID 33767177 · DOI 10.1038/s41392-021-00506-6
4. The Evasion Mechanisms of Cancer Immunity and Drug Intervention in the Tumor Microenvironment.
   Kim SK, Cho SW. · · 2022 · cited 300× · PMID 35685630 · DOI 10.3389/fphar.2022.868695
5. Tumor-associated macrophages: potential therapeutic strategies and future prospects in cancer.
   Li C, Xu X, Wei S, Jiang P, et al · · 2021 · cited 259× · PMID 33504575 · DOI 10.1136/jitc-2020-001341
6. Targeting CD47 for cancer immunotherapy.
   Jiang Z, Sun H, Yu J, Tian W, et al · · 2021 · cited 254× · PMID 34717705 · DOI 10.1186/s13045-021-01197-w
7. Current Strategies to Target Tumor-Associated-Macrophages to Improve Anti-Tumor Immune Responses.
   Anfray C, Ummarino A, Andón FT, Allavena P. · · 2019 · cited 222× · PMID 31878087 · DOI 10.3390/cells9010046
8. Emerging phagocytosis checkpoints in cancer immunotherapy.
   Liu Y, Liu Y, Wang Y, Yang Y, et al · · 2023 · cited 186× · PMID 36882399 · DOI 10.1038/s41392-023-01365-z